Stem Cell Sciences plc
27 July 2006
27.7.06 Immediate Release
(Stem Cell Sciences plc. AIM: STEM)
NON-EXECUTIVE DIRECTOR APPOINTMENT
Stem Cell Sciences plc (AIM:STEM) is pleased to announce that
Jeremy Paul Scudamore, aged 59, has been appointed to the Stem Cell Sciences
Board of Directors as Non-executive Director with immediate effect.
Jeremy Scudamore was educated at Nottingham University. He joined I.C.I. as an
Economist and worked for the I.C.I. Group and later Zeneca in a number of
international commercial and strategic management roles. He has considerable
experience of Business in the Americas, Europe, Africa the Middle East and Asia.
He became Business Director for Zeneca Agrochemicals, Managing Director of
Zeneca Seeds and Plant science and then Chief Executive Officer of Zeneca
Specialties. In 1998/9 he led the £1.3bn buyout of Zeneca Specialties from
AstraZeneca to form the Avecia Group. At the time, this was the largest ever
buyout in Europe. He was appointed CEO and later Chairman of the Avecia Group.
Having restructured and successfully divested all but the Biotechnology
businesses, he retired in 2006.
Jeremy has been Chair of the UK Chemicals Innovation team for the DTI, was on
the Boards of the Chemical Industry Association, Chemical and Engineering News
(Washington USA), European Chemical News, and was Chairman of Cyprotex plc.
Jeremy is currently a Non -executive Director of ARM Holdings plc and Chair of
the North West Science Council.
Peter Mountford, CEO of Stem Cell Sciences commented; "Jeremy has extensive
expertise in growing global businesses and maximising shareholder value. He is
a valuable addition to our Board. We are thrilled to have him on the team and
look forward to working with him."
Current Appointments Held:
Company Name Position Appointed
ARM HOLDINGS PLC Director 26/04/2004
Past Appointments Held:
Company Name Position Appointed Resigned
ADVANTA RESEARCH LIMITED Director 06/02/1995 15/05/1998
ADVANTA TECHNOLOGY LIMITED Director 01/12/1995 15/05/1998
AVECIA BIOTECH PROPERTIES LIMITED Director 30/03/2005 04/10/2005
AVECIA FINE CHEMICALS LIMITED Director 18/02/2005 16/09/2005
AVECIA FINANCE PLC Director 23/06/1999 22/03/2006
AVECIA GROUP PLC Director 23/06/1999 22/03/2006
AVECIA HOLDINGS PLC Director 23/06/1999 22/03/2006
AVECIA 10 LIMITED Director 23/06/1999 17/03/2006
AVECIA CORPORATION LIMITED Director 23/06/1999 22/03/2006
AVECIA LIMITED Director 23/06/1999 22/03/2006
AVECIA PHARMACEUTICALS LIMITED Director 21/02/2005 02/12/2005
AVECIA INKJET LIMITED Director 18/02/2005 17/02/2006
AVECIA INVESTMENTS LIMITED Director 13/07/1999 22/03/2006
AVECIA TRADING LIMITED Director 23/06/1999 31/07/2003
AVECIA TONER RESINS LIMITED Director 23/06/1999 04/10/2005
AVECIA UK HOLDINGS LIMITED Director 23/06/1999 22/03/2006
AV NO. 2 LIMITED Director 22/01/2002 22/03/2006
AV NO.3 LIMITED Director 23/06/1999 19/04/2004
CHEMICAL INDUSTRIES ASSOCIATION LIMITED Director 20/05/2000 03/01/2006
CYPROTEX SERVICES LIMITED Director 04/12/2001 17/02/2003
ICI(NOMINEE HOLDINGS) LIMITED Director 06/09/1992 04/01/1994
ILIAD 3 LIMITED Director 23/06/1999 30/03/2004
ZENECA INTERNATIONAL LIMITED Director 15/09/1993 01/07/1997
- Ends -
For further information, please contact:
Stem Cell Sciences plc
Peter Mountford, Chief Executive Officer 0131 662 9829
Weber Shandwick Square Mile 020 7067 0700
James Chandler/James White
Notes to Editors
Stem Cell Sciences plc (SCS, AIM: STEM) is a global biotechnology company
providing products in the burgeoning stem cell research and drug discovery
markets, in addition to the targeted development of cell-based therapies for
neurodegenerative disease and injury.
The Company has established a leading intellectual property (IP) and technology
portfolio that enables the commercial application of stem cells in drug
discovery, providing the Company with early-stage revenue streams and technology
development for at scale cell production of SCS cell-based therapeutics.
SCS principal focus is in neurological disease. Revenues in the neurotech
market, including pharmaceuticals, devices and diagnostics, grew 10% in 2005 to
US$110 billion*.
SCS operates as a group of independent operations with laboratories in Scotland,
Japan and Australia, each of which is affiliated with an academic centre of
excellence. These include the Institute of Stem Cell Research (ISCR), Edinburgh,
UK, RIKEN Centre for Development Biology, Kobe, Japan and the Australian Stem
Cell Centre, Melbourne, Australia.
SCS has four business units focused on key sustainable business strategies.
SC Proven(TM)provides cell culture media (liquid formulations) and reagents that
enable the growth and differentiation of stem cells. The first commercially
available product, a novel, serum free, stem cell growth medium, has been
exclusively licensed for manufacture and marketing to Chemicon, a division of
Serologicals Inc.
SC Licensing licenses SCS proprietary technologies, such as Internal Ribosome
Entry Site (IRES) and Stem Cell Selection, for application in laboratory-based
research and discovery. SCS has licensed technology to major pharmaceutical and
biotechnology companies including Pfizer, Sanofi Aventis, GSK, Deltagen Inc and
Lexicon Genetics Inc.
SC Services provides specialised stem cell production for basic research and
drug discovery, including high-throughput applications.
SC Therapies goal is to develop safe and effective cell-based therapies for
currently incurable diseases. SCS is conducting preclinical evaluations of its
neural stem cell lines in a number of therapeutic applications. The first
preclinical programme is being undertaken by SCS' Japanese affiliate, which
recently announced the exclusive licensing of human multi-potent adipose-derived
stem (hMADS) cells for therapeutic purposes. SCS KK will conduct preclinical
studies for the treatment of Duchene's Muscular Dystrophy in 2006.
This information is provided by RNS
The company news service from the London Stock Exchange
QDBEBBV
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.